Skip to main content
. 2018 Apr 17;9(29):20590–20604. doi: 10.18632/oncotarget.25020

Figure 2. Response of aGVHD at day 30 (d30) and within the 90 days (<90d) after initiation of MSC therapy.

Figure 2

(A) overall response, (B) organ specific response (skin n = 17; GI tract n = 26; liver n = 11). CR, complete response of aGVHD; GI, gastrointestinal tract; PR, partial response of aGVHD. The differences between skin, GI and liver response rates (CR, PR and overall response) were not statistically significant, both at day 30 (d30) and within the 90 day-period (<90d) after first MSC infusion (p = NS).